Combinatorial chemistry technology: method – library – apparatus – Method of creating a library – Solid-phase synthesis or particular method of cleavage from...
Reexamination Certificate
2011-03-22
2011-03-22
Low, Christopher (Department: 1639)
Combinatorial chemistry technology: method, library, apparatus
Method of creating a library
Solid-phase synthesis or particular method of cleavage from...
C506S005000, C506S026000, C506S016000
Reexamination Certificate
active
07910523
ABSTRACT:
The present invention includes composition and methods for making and using a combinatorial library to identify modified thioaptamers that bind to, and affect the immune response of a host animal, transcription factors such as IL-6, NF-κB, AP-1 and the like. Composition and methods are also provided for the treatment of viral infections, as well as, vaccines and vaccine adjuvants are provided that modify host immune responses.
REFERENCES:
patent: 5218088 (1993-06-01), Gorenstein
patent: 5270163 (1993-12-01), Gold et al.
patent: 5397698 (1995-03-01), Goodman
patent: 5436327 (1995-07-01), Southern et al.
patent: 5475096 (1995-12-01), Gold et al.
patent: 5503978 (1996-04-01), Schneider et al.
patent: 5510240 (1996-04-01), Lam et al.
patent: 5563050 (1996-10-01), Peyman et al.
patent: 5576302 (1996-11-01), Cook
patent: 5582981 (1996-12-01), Toole et al.
patent: 5587361 (1996-12-01), Cook
patent: 5599797 (1997-02-01), Cook
patent: 5602000 (1997-02-01), Hyman
patent: 5607923 (1997-03-01), Cook
patent: 5620963 (1997-04-01), Cook
patent: 5635488 (1997-06-01), Cook
patent: 5639603 (1997-06-01), Dower et al.
patent: 5639873 (1997-06-01), Barascut
patent: 5652355 (1997-07-01), Metelev et al.
patent: 5660985 (1997-08-01), Pieken
patent: 5661134 (1997-08-01), Cook
patent: 5663153 (1997-09-01), Hutcherson et al.
patent: 5668265 (1997-09-01), Nadeau et al.
patent: 5670637 (1997-09-01), Gold et al.
patent: 5696249 (1997-12-01), Gold et al.
patent: 5705337 (1998-01-01), Gold
patent: 5734041 (1998-03-01), Just
patent: 5750666 (1998-05-01), Caruthers et al.
patent: 5756291 (1998-05-01), Griffin et al.
patent: 5763595 (1998-06-01), Gold
patent: 5770367 (1998-06-01), Southern et al.
patent: 5795721 (1998-08-01), Rabin
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5804445 (1998-09-01), Brasier
patent: 5811533 (1998-09-01), Gold et al.
patent: 5844106 (1998-12-01), Seela et al.
patent: 5853984 (1998-12-01), Davis
patent: 5874219 (1999-02-01), Rava
patent: 6011020 (2000-01-01), Gold et al.
patent: 6069008 (2000-05-01), Bennett et al.
patent: 6120763 (2000-09-01), Fakhrai et al.
patent: 6171792 (2001-01-01), Brent et al.
patent: 6180348 (2001-01-01), Li
patent: 6242246 (2001-06-01), Gold
patent: 6319668 (2001-11-01), Nova et al.
patent: 6346611 (2002-02-01), Pagratis et al.
patent: 6369208 (2002-04-01), Cole et al.
patent: 6423493 (2002-07-01), Gorenstein
patent: 6458543 (2002-10-01), Gold
patent: 6503715 (2003-01-01), Gold
patent: 6514948 (2003-02-01), Raz et al.
patent: 6544776 (2003-04-01), Gold
patent: 6551795 (2003-04-01), Rubenfield et al.
patent: 6569630 (2003-05-01), Vivekananda et al.
patent: 6610504 (2003-08-01), Yuan
patent: 6713616 (2004-03-01), Pagratis et al.
patent: 6716629 (2004-04-01), Hess et al.
patent: 6780582 (2004-08-01), Wagner et al.
patent: 6867289 (2005-03-01), Gorenstein et al.
patent: 7125660 (2006-10-01), Stanton et al.
patent: 2001/0014461 (2001-08-01), Hutchens et al.
patent: 2001/0014479 (2001-08-01), Hutchens et al.
patent: 2001/0034330 (2001-10-01), Kensil
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2003/0144229 (2003-07-01), Klinman et al.
patent: 2003/0162190 (2003-08-01), Gorenstein et al.
patent: 2003/0162216 (2003-08-01), Gold et al.
patent: 2003/0186906 (2003-10-01), Schlingensiepen et al.
patent: 2004/0191905 (2004-09-01), Stevenson et al.
patent: 2004/0242521 (2004-12-01), Gorenstein et al.
patent: 0 568 925 (1993-11-01), None
patent: 0 855 184 (1998-07-01), None
patent: 1 157 132 (2001-11-01), None
patent: 89/02472 (1989-03-01), None
patent: WO 92 14842 (1992-09-01), None
patent: WO 92 14843 (1992-09-01), None
patent: WO 93 08296 (1993-04-01), None
patent: 94/01550 (1994-01-01), None
patent: WO 96 19572 (1996-06-01), None
patent: 96/28457 (1996-09-01), None
patent: WO 99 31275 (1999-06-01), None
patent: 99/54506 (1999-10-01), None
patent: 00/24404 (2000-05-01), None
patent: WO 00 47774 (2000-08-01), None
patent: WO 96 41019 (2000-08-01), None
patent: 03 50290 (2003-06-01), None
patent: 2004/026260 (2004-04-01), None
patent: 2005/003291 (2005-01-01), None
patent: 2005/018357 (2005-03-01), None
patent: 2005/032455 (2005-04-01), None
patent: 2005/037053 (2005-04-01), None
P. Sazani, et al. Nuclear antisense effects of neutral anionic and cationic oligonucleotide analogs. 2001 Nucleic Acids Research 29:3965-3974.
G. Elgemeie Thioguanine, Mercaptoputine: Their analogs and nucleosides as antimetabolites 2003 Current Pharmaceutical Design 2627-2642.
K. Kanaori, et al. Effect of phosphorothioate chiraliy on i-Motif structure and stability. 2004 Biochemistry 43:5672-5679.
X. Yang, et al Aptamers containing thymidine 3' O-phosphorodithioates:synthesis and binding to nuclear factor κB. 1999 Bioorganic & Medicinal Letters9: 3357-3362.
L. Cassiday et al. Binding Stoichiometry of a RNA aptamer and its transcription factor target. 2002 Analytical Biochemistry 306:290-297.
S. Raveh et al. Peptidic determinants and structural model of human NDP kinase B bound to single-stranded DNA. 2001 Biochemistry 40:5882-5893.
Doucette et al. 2001 Proteomics 1:987-1000.
Gish et al (1988 Science 240:1520-1522).
PCT International Search Report and Written Opinion of the International Searching Authority, PCT/US04/16061, Jul. 10, 2006.
Antsypovich, et al. (1998) Cross-linked DNA duplexes: Exonuclease stability and interaction with the nucleic transcription factor of the κ light-chain enhancer (Nf- κB).
Bielinska, et al. (1990) Regulation of Gene Expression with Double-Stranded Phosphorothioate Oligonucleotides,Science, vol. 250, pp. 997-1000.
Khaled, et al. (1998) Use of Phosphorothioate-Modified Oligodeozynucleotides to inhibit NF- κB Expression and Lymphocyte Function,Clinical Immunology and Immunopathology, vol. 86, No. 2, pp. 170-179.
King, et al., (1998) Novel Combinatorial Selection of Phosphorothioate Oligonucleotide Aptamers.Biochemistry, 37, 16489-16493.
Kunsch, et al. (1992) Selection of Optimal κB/Rel DNA-Binding Motifs: Interaction of Both Subunits of NF-κB with DNA is Required for Transcriptional Activation,Molecular and Cellular Biology, Oct. 1992, vol. 12, No. 10, p. 4412-4421.
Lebruska, et al. (1999) Selection and Characterization of an RNA Decoy for Transcription Factor NF-κBimg id="CUSTOM-CHARACTER-00001" he="3.13mm" wi="1.78mm" file="US07910523-20110322-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?,Biochemistry, 38, 3168-3174.
Morishita, et al. (1997) In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarction,Nature Medicine, vol. 3, No. 8, p. 894-899.
Nakamaye, et al. (1988) Direct sequencing of polymerase chain reaction amplified DNA fragments through the incorporation of deoxynucleoside α-thiotriphosphates,Nucleic Acids Research, vol. 16, No. 21.
Sharma, et al. (1996) Transcription Factor Decoy Approach to Decipher the Role of NF- κB in Oncogenesis,Anticancer Research, 16:61-70.
Stec, et al. (1997) Deoxyribonucleoside 3'-O-(2-Thio- and 2-Oxo-“spiro”-4,4-pentamethylene-1,3,2-oxathiaphospholane)s: Monomers for Stereocontrolled Synthesis of Oligo(deoxyribonucleoside phosphorothioate)s and Chimeric PS/PO Oligonucleotides§,J. Am. Chem. Soc., 120, 7156-7167.
Uhlmann, et al. (1997) Studies on the Mechanism of Stabilization of Partially Phosphorothioated Oligonucleotides Against Nucleolytic Degradation,Antisense&nucleic Acid Drug Development, 7:345-350.
Zon, Gerald (1988) Oligonucleotide Analogues as Potential Chemotherapeutic Agents. Pharmaceutical Research, vol. 5, No. 9, pp. 539-549.
Amarzguioui, M., et al., Nuc Acids Res, 31, 589-595, (2003)—Tolerance for mutations and chemical modifications in a siRNA.
Braasch, D.A., et al., Nucleic Acids Res, 30(23), 5160-7 (2002) -Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design.
Braasch, D.A. and D.R. Corey, Biochemistry, 41, 4503-4510 (2002)—Novel antisense and peptide nucleic acid strategies for co
Gorenstein David G.
Leary James
Luxon Bruce A.
Board of Regents , The University of Texas System
Chalker Flores LLP
Flores Edwin S.
Gross Christopher M.
Low Christopher
LandOfFree
Structure based and combinatorially selected oligonucleoside... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Structure based and combinatorially selected oligonucleoside..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Structure based and combinatorially selected oligonucleoside... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2759197